According to a recent study, low-dose oral bisphosphonates administered to prevent or treat postmenopausal osteoporosis may be associated with a lower risk of skeletal metastasis in patients with early- or more advanced-stage breast cancer.
According to a recent study, low-dose oral bisphosphonates administered to prevent or treat postmenopausal osteoporosis may be associated with a lower risk of skeletal metastasis in patients with early- or more advanced-stage breast cancer.
The findings are based on analysis of health administrative data from a historical cohort of 21,664 women diagnosed with breast cancer in Quebec, Canada. Researchers from McGill University Health Centre stratified the cohort according to disease stage (0-II or III) at time of diagnosis. The primary outcome was time to development of bone metastasis. Exposure was considered bisphosphonate use prediagnosis, postdiagnosis, both, or neither, and a cumulative index of drug exposure.
In women with local disease at diagnosis, use of bisphosphonates only postdiagnosis or continuing on them after breast cancer diagnosis was associated with a decline in risk of bone metastasis from 45% to 28%. The reduction in risk associated with bisphosphonates was nearly 50% in women with regional disease who used the drugs postdiagnosis, regardless of whether they had used bisphosphonates prediagnosis.
Researchers also observed a statistically significant dose-response trend that related increased use with lower risk (slope = 0.94, 95% confidence interval = 0.90 to 0.99). Also, bisphosphonates were associated with a decreased risk of all-cause mortality similar to that for development of bone metastasis.
Editorial: Graduate medical education at crossroads
Investigators concluded that low-dose bisphosphonates used for the prevention or treatment of postmenopausal osteoporosis were tied to lower risk of skeletal metastasis in patients with early- and advanced-stage breast cancer.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
Tocolysis use after PPROM not linked to neurodevelopmental outcomes
May 29th 2024A recent study investigated the effects of antenatal tocolysis on neurodevelopmental outcomes among children aged 5.5 years following preterm prelabor rupture of membranes, revealing no significant differences in outcomes.
Read More
Study finds youth with developmental disabilities less likely to access reproductive health care
May 22nd 2024A recent study reveals that adolescents with autism and other developmental disabilities have fewer visits to obstetrician-gynecologists and lower hormonal contraceptive use compared to their typically developing peers, highlighting a need for improved reproductive health services.
Read More
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More